Sugi Predict

Sugi Predict / Compounds / SCHEMBL2080149

SCHEMBL2080149

SCHEMBL2080149

COC(=O)c1ccc(-c2nc(CCl)c(C)o2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ SMN1; SMN2 Q16637 6/20 0.53
▸ MAPT P10636 6/20 0.53
▸ ALDH1A1 P00352 5/20 0.53
▸ HSD17B10 Q99714 5/20 0.53
▸ RAB9A P51151 4/20 0.53
▸ KDM4E B2RXH2 4/20 0.53
▸ NPC1 O15118 3/20 0.53
▸ HPGD P15428 2/20 0.53
▸ NFKB1 P19838 1/20 0.53
▸ NFKB2 Q00653 1/20 0.53
▸ RELA Q04206 1/20 0.53
▸ ATM Q13315 1/20 0.53
▸ HRH1 P35367 1/20 0.53
▸ LMNA P02545 1/20 0.51
▸ TP53 P04637 3/20 0.49
▸ THRB P10828 2/20 0.49
▸ USP2 O75604 1/20 0.46
▸ ALOX15 P16050 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15325997 0.88 MEN1 (0.58) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL12469009 0.86 MEN1 (0.57) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL2078397 0.85 KDM4E (0.52) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL15430774 0.85 MAPT (0.53) MAPTHSD17B10RAB9AKDM4EHPGD
SCHEMBL15323450 0.85 KDM4E (0.55) MAPTHSD17B10RAB9AKDM4ENPC1
SCHEMBL12469625 0.83 MEN1 (0.54) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL12469332 0.83 MEN1 (0.54) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL12468701 0.83 MEN1 (0.54) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL4851280 0.82 PPARG (0.46) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL12468892 0.82 MEN1 (0.53) MEN1KMT2ASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296732-B2 Substituted benzamides and their uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2016-03-29 — — US disclosed
US-9296732-B2 Substituted benzamides and their uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2016-03-29 — — US disclosed
US-9296732-B2 Substituted benzamides and their uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2016-03-29 — — US disclosed
US-20150329503-A1 SUBSTITUTED BENZAMIDES AND THEIR USES UNIV LELAND STANFORD JUNIOR (US) 2015-11-19 — — US disclosed
US-20150329503-A1 SUBSTITUTED BENZAMIDES AND THEIR USES UNIV LELAND STANFORD JUNIOR (US) 2015-11-19 — — US disclosed
US-20150329503-A1 SUBSTITUTED BENZAMIDES AND THEIR USES UNIV LELAND STANFORD JUNIOR (US) 2015-11-19 — — US disclosed
US-9095582-B2 Substituted aryloxazoles and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-08-04 — — US disclosed
US-9095582-B2 Substituted aryloxazoles and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-08-04 — — US disclosed
US-9085570-B2 Substituted benzamides and their uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-07-21 — — US disclosed
US-9085570-B2 Substituted benzamides and their uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-07-21 — — US disclosed
EP-1756096-A1 INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2007-02-28 — — EP disclosed
US-7173048-B2 Indolyl derivatives as liver-X-receptor (LXR) modulators HOFFMANN-LA ROCHE INC. (US) 2007-02-06 — — US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 — — US disclosed
WO-2006037480-A1 HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-04-13 — — WO disclosed
US-20060074115-A1 Novel hexafluoroisopropanol substituted ether derivatives HOFFMANN-LA ROCHE INC. 2006-04-06 — — US disclosed
US-20060004068-A1 Novel hexafluoroisopropanol derivatives F. HOFFMANN-LA ROCHE AG (CH) 2006-01-05 — — US disclosed
WO-2006000323-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-01-05 — — WO disclosed
WO-2005105791-A1 INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-11-10 — — WO disclosed
US-20050245515-A1 Indolyl derivatives as liver-X-receptor (LXR) modulators F. HOFFMANN-LA ROCHE AG (CH) 2005-11-03 — — US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245515-A1 Indolyl derivatives as liver-X-receptor (LXR) modulators INSR, NR1H2, NR1H3 MEN1 1598/4885KMT2A 2809/4885SMN1; SMN2 4376/4885
US-20150329503-A1 SUBSTITUTED BENZAMIDES AND THEIR USES NISCH, BTD, NAAA MEN1 2797/4885KMT2A 459/4885SMN1; SMN2 500/4885
US-20060074115-A1 Novel hexafluoroisopropanol substituted ether derivatives NR1H3, NR1H2, NR1I2 MEN1 3755/4885KMT2A 2634/4885SMN1; SMN2 4639/4885
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 MEN1 3268/4885KMT2A 1792/4885SMN1; SMN2 4339/4885
US-20060004068-A1 Novel hexafluoroisopropanol derivatives NR1H3, NR1H2, NR1I2 MEN1 2717/4885KMT2A 3063/4885SMN1; SMN2 4516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.